Weiss R B, Charles L M, Macdonald J S
Cancer Clin Trials. 1980 Fall;3(3):203-9.
m-AMSA is a new drug in the National Cancer Institute Drug Development Program. The drug has moderate but tolerable toxicity and has demonstrated tumor activity in acute leukemia and breast cancer. Numerous phase II studies are completed or in progress and phase III trials will soon begin. We review the preclinical and phase I clinical information on this drug. We then enumerate the present ongoing studies and make some suggestions for future studies that will allow a rapid and orderly assessment of its value.
m-AMSA是美国国立癌症研究所药物开发项目中的一种新药。该药物具有中度但可耐受的毒性，并且已在急性白血病和乳腺癌中显示出肿瘤活性。众多的II期研究已经完成或正在进行，III期试验即将开始。我们回顾了关于这种药物的临床前和I期临床信息。然后我们列举了目前正在进行的研究，并对未来的研究提出了一些建议，以便能够快速、有序地评估其价值。
